Subtopic Deep Dive
Multiple Myeloma Genomic Abnormalities
Research Guide
What is Multiple Myeloma Genomic Abnormalities?
Multiple Myeloma Genomic Abnormalities refer to cytogenetic and molecular alterations such as t(4;14), del(17p), and gain(1q) identified through sequencing and profiling that drive risk stratification and prognosis in multiple myeloma patients.
Sequencing studies reveal high-risk features like t(4;14) and del(17p) in newly diagnosed patients, correlating with poor survival (Avet-Loiseau et al., 2007; 898 citations). Gene expression profiling classifies molecular subgroups from CD138+ plasma cells (Broyl et al., 2010; 336 citations). Multi-region sequencing uncovers spatial genomic heterogeneity and clonal evolution (Rasche et al., 2017; 400 citations). Over 10 key papers span 2007-2022.
Why It Matters
Genomic abnormalities enable risk-adapted therapy, as bortezomib improves outcomes in t(4;14) but not del(17p) patients (Avet-Loiseau et al., 2010; 419 citations). Mayo mSMART guidelines stratify treatment based on these features for newly diagnosed symptomatic myeloma (Kumar et al., 2009; 621 citations). R-ISS incorporates abnormalities for precise prognostication, guiding therapies like daratumumab in high-risk cases (D’Agostino et al., 2022; 365 citations; Façon et al., 2019; 942 citations). Single-cell and spatial analyses predict clonal evolution, personalizing interventions.
Key Research Challenges
Detecting High-Risk Cytogenetics
Identifying t(4;14), del(17p), and gain(1q) requires FISH or sequencing, but prevalence varies across cohorts (Avet-Loiseau et al., 2007). Standardization challenges persist despite guidelines (Kumar et al., 2009). Flow cytometry aids but needs multiparametric consensus (Rawstron et al., 2008).
Prognosticating Clonal Heterogeneity
Multi-region sequencing shows spatial genomic diversity complicating survival predictions (Rasche et al., 2017). Gene expression subgroups overlap with cytogenetics, hindering pure classification (Broyl et al., 2010). R-ISS revisions integrate but intermediate-risk gaps remain (D’Agostino et al., 2022).
Targeting Specific Alterations
Bortezomib benefits t(4;14) but fails del(17p), demanding tailored drugs (Avet-Loiseau et al., 2010). BCMA targeting emerges, but genomic context for resistance unclear. Molecular profiling needed for precision (Broyl et al., 2010).
Essential Papers
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Thierry Façon, Shaji Kumar, Torben Plesner et al. · 2019 · New England Journal of Medicine · 942 citations
Among patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation, the risk of disease progression or death was significantly lower among those who r...
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Hervé Avet‐Loiseau, Michel Attal, Philippe Moreau et al. · 2007 · Blood · 898 citations
Abstract Acquired genomic aberrations have been shown to significantly impact survival in several hematologic malignancies. We analyzed the prognostic value of the most frequent chromosomal changes...
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Shaji Kumar, Joseph Mıkhael, Francis K. Buadi et al. · 2009 · Mayo Clinic Proceedings · 621 citations
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Andy C. Rawstron, Alberto Órfão, Meral Beksaç et al. · 2008 · Haematologica · 507 citations
The European Myeloma Network (EMN) organized two flow cytometry workshops. The first aimed to identify specific indications for flow cytometry in patients with monoclonal gammopathies, and consensu...
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
Nina Shah, Ajai Chari, Emma Scott et al. · 2020 · Leukemia · 465 citations
Abstract Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duratio...
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Hervé Avet‐Loiseau, Xavier Leleu, Murielle Roussel et al. · 2010 · Journal of Clinical Oncology · 419 citations
Purpose Cytogenetics is an important prognostic parameter in multiple myeloma (MM). Patients presenting with either t(4;14) or del(17p) are known to have a short event-free survival (EFS) and overa...
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
Leo Rasche, Shweta S. Chavan, Owen Stephens et al. · 2017 · Nature Communications · 400 citations
Reading Guide
Foundational Papers
Start with Avet-Loiseau et al. (2007; 898 citations) for core survival links of t(4;14)/del(17p), then Kumar et al. (2009; 621 citations) mSMART for guidelines, and Avet-Loiseau et al. (2010; 419 citations) for therapy responses.
Recent Advances
Study Rasche et al. (2017; 400 citations) for spatial heterogeneity, D’Agostino et al. (2022; 365 citations) R2-ISS refinements integrating genomics.
Core Methods
FISH cytogenetics (Avet-Loiseau et al., 2007), gene expression profiling (Broyl et al., 2010), multi-region sequencing (Rasche et al., 2017), flow cytometry (Rawstron et al., 2008).
How PapersFlow Helps You Research Multiple Myeloma Genomic Abnormalities
Discover & Search
Research Agent uses searchPapers for 't(4;14) del(17p) multiple myeloma' retrieving Avet-Loiseau et al. (2007), then citationGraph maps 898 citing papers on survival impacts, and findSimilarPapers links to Rasche et al. (2017) on heterogeneity.
Analyze & Verify
Analysis Agent applies readPaperContent to extract del(17p) outcomes from Avet-Loiseau et al. (2010), verifies survival stats via verifyResponse (CoVe) against R-ISS data (D’Agostino et al., 2022), and runPythonAnalysis computes risk correlations with GRADE scoring for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in del(17p) targeting post-bortezomib (Avet-Loiseau et al., 2010), flags contradictions in subgroup classifications (Broyl et al., 2010), while Writing Agent uses latexEditText, latexSyncCitations for risk-stratified review, and latexCompile for publication-ready manuscript.
Use Cases
"Analyze survival data from genomic abnormalities in Avet-Loiseau 2007 and 2010 papers using Python."
Research Agent → searchPapers → Analysis Agent → readPaperContent (extracts tables) → runPythonAnalysis (pandas survival curves, Kaplan-Meier stats) → matplotlib plot of t(4;14) vs del(17p) outcomes.
"Write LaTeX section on mSMART guidelines incorporating Kumar 2009 and recent R-ISS."
Research Agent → citationGraph → Synthesis Agent → gap detection → Writing Agent → latexEditText (drafts section) → latexSyncCitations (adds Kumar et al., 2009; D’Agostino et al., 2022) → latexCompile (PDF with risk table).
"Find code for multi-region sequencing analysis like Rasche 2017."
Research Agent → paperExtractUrls (Rasche et al., 2017) → paperFindGithubRepo → githubRepoInspect (clonal evolution scripts) → runPythonAnalysis (reproduces heterogeneity metrics).
Automated Workflows
Deep Research workflow scans 50+ papers on del(17p) via searchPapers → citationGraph → structured report with GRADE-graded evidence from Avet-Loiseau et al. (2007, 2010). DeepScan applies 7-step CoVe to verify t(4;14) bortezomib claims, checkpointing against Kumar mSMART (2009). Theorizer generates hypotheses on gain(1q) targeting from Broyl profiling (2010) and Rasche heterogeneity (2017).
Frequently Asked Questions
What defines Multiple Myeloma Genomic Abnormalities?
Cytogenetic alterations like t(4;14), del(17p), and gain(1q) identified by FISH/sequencing, impacting survival (Avet-Loiseau et al., 2007).
What methods detect these abnormalities?
FISH for cytogenetics, gene expression profiling on CD138+ cells, multi-region sequencing for heterogeneity (Broyl et al., 2010; Rasche et al., 2017).
What are key papers?
Avet-Loiseau et al. (2007; 898 citations) on survival, Kumar et al. (2009; 621 citations) mSMART, Avet-Loiseau et al. (2010; 419 citations) on bortezomib.
What open problems exist?
Targeting del(17p) resistance, resolving intermediate R-ISS risks, modeling clonal evolution spatially (D’Agostino et al., 2022; Rasche et al., 2017).
Research Multiple Myeloma Research and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Multiple Myeloma Genomic Abnormalities with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers